Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.Sumanta Kumar Pal, Cristina Suárez, Mohan Liu et al.|Journal of Clinical Oncology|2024Cited by 1